BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7497436)

  • 1. Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy.
    Cox-Froncillo MC; Cantonetti M; Masi M; Lentini R; Giudiceandrea P; Maffei L; Tribalto M; Amadori S; Papa G
    Cancer Genet Cytogenet; 1995 Oct; 84(1):15-8. PubMed ID: 7497436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
    Itoh T; Tamura S; Takemoto Y; Kakishita E
    Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FISH analysis for CML monitoring?
    Froncillo MC; Maffei L; Cantonetti M; Del Poeta G; Lentini R; Bruno A; Masi M; Tribalto M; Amadori S
    Ann Hematol; 1996 Sep; 73(3):113-9. PubMed ID: 8841098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
    Song YQ; Li W; Kong LH; Wang GJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha).
    Steegmann JL; Requena MJ; Casado LF; Pico M; Peñarrubia MJ; Ferro MT; Resino M; Fernandez-Rañada JM
    Am J Hematol; 1996 Nov; 53(3):169-74. PubMed ID: 8895687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias.
    Amare PS; Baisane C; Saikia T; Nair R; Gawade H; Advani S
    Cancer Genet Cytogenet; 2001 Dec; 131(2):125-34. PubMed ID: 11750052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy.
    Tchirkov A; Giollant M; Tavernier F; Briançon G; Tournilhac O; Kwiatkowski F; Philippe P; Choufi B; Deméocq F; Travade P; Malet P
    Br J Haematol; 1998 Jun; 101(3):552-7. PubMed ID: 9633901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of minimal residual disease in patients with chronic myeloid leukaemia on IFN-alpha 2b therapy using conventional cytogenetics and fluorescence in situ hybridization.
    Talwar R; Choudhry VP; Jobanputra V; Kucheria K
    Natl Med J India; 2002; 15(4):195-8. PubMed ID: 12296472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
    Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
    J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of remission status by fluorescence in situ hybridisation in chronic myeloid leukaemia patients treated with interferon-alpha.
    Duba HC; Peter S; Hilbe W; Fluckinger T; Fridrik M; Erdel M; Thaler J; Utermann G
    Int J Oncol; 1999 Jan; 14(1):145-50. PubMed ID: 9863021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment.
    Mühlmann J; Thaler J; Hilbe W; Bechter O; Erdel M; Utermann G; Duba HC
    Genes Chromosomes Cancer; 1998 Feb; 21(2):90-100. PubMed ID: 9491319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha].
    Hong H; Qiu JY; Lai YY; Shi Y; He Q; Dang H; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):269-73. PubMed ID: 12844411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
    Kurzrock R; Estrov Z; Kantarjian H; Talpaz M
    J Clin Oncol; 1998 Apr; 16(4):1526-31. PubMed ID: 9552062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis.
    Cuneo A; Bigoni R; Emmanuel B; Smit E; Rigolin GM; Roberti MG; Bardi A; Piva N; Scapoli G; Castoldi G; Van Den Berghe H; Hagemeijer A
    Leukemia; 1998 Nov; 12(11):1718-23. PubMed ID: 9823946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Rios MB; Majlis A; Keating M; Freireich EJ; Kantarjian H
    J Clin Oncol; 1998 Oct; 16(10):3279-85. PubMed ID: 9779702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Philadelphia chromosome in chronic myelogenous leukemia: confirmation of cytogenetic diagnosis in Ph positive and negative cases by fluorescence in situ hybridization.
    Acar H; Stewart J; Connor MJ
    Cancer Genet Cytogenet; 1997 Apr; 94(2):75-8. PubMed ID: 9109930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Cortes J; Kantarjian H; O'Brien S; Kurzrock R; Keating M; Talpaz M
    Leukemia; 1998 Jun; 12(6):860-4. PubMed ID: 9639411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.